hotspot -WSS

hotspot

author：knowledge 2025-09-07 17:17:07 - browse：16516

Duchenne muscular dystrophy Histopathology — Duchenne muscular dystrophy histopathology. Dr. Edwin P. Ewing, Jr./CDC

Japanese drugmaker Nippon Shinyaku said on Monday that its Duchenne muscular dystrophy drug, Viltepso, part of a controversial class of treatments for the rare disease, had failed to reach its primary endpoint in a placebo-controlled confirmatory trial.

Children who received the drug could stand up faster from the floor at the end of the study, but so could children who received a placebo. There was no statistically significant difference between the groups.

Although Nippon did not release detailed data, the failure is notable because Viltepso belongs to a contentious class of drugs called exon-skippers. Duchenne is caused by mutations in a muscle-supporting gene called dystrophin. These drugs are designed to increase the amount of dystrophin protein that patients with specific mutations produce. But the drugs only lead to slight increases in protein levels, and their clinical benefits have never been proven in a large, placebo-controlled study.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Telehealth for opioid use disorder is lifesaving

WSS

How housing is health care on Long Island

Explaining an after

WATCH: Why do bright lights make us see spots?

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Telehealth for opioid use disorder is lifesaving

The health care issue Democrats can’t solve: hospital reform

Wikipedia

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

As demand for Covid shots wanes, Moderna seeks its next success

Inari Medical to buy amputation prevention company LimFlow

Cancer drug shortages should be causing more outrage

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

The cancer drug shortage isn’t new — and neither are the solutions

How to convince healthy people to buy insurance

ChatGPT in medicine: STAT answers readers' burning questions

How housing is health care on Long Island

Medicare proposal to cover medical devices draws a mixed reaction

How housing is health care on Long Island

focus

Key Senate panel to consider PBM, drug pricing reform package

New weight loss drugs vying to be the next Wegovy or Mounjaro

Popular nasal decongestant doesn't actually relieve congestion

New Covid vaccine is recommended for everyone 6 months or older

All of Us, NIH's precision medicine initiative, gets a big boost

Life sciences investors close nearly $6 billion in new funds

hotspot

hotspot

explore

entertainment